Index by author

February 01, 2023; Volume 90,Issue 2

  1. Zust, Christopher

    1. What are the treatment options for myasthenia gravis if first-line agents fail?
      Christopher Zust, MD and John A. Morren, MD
      Cleveland Clinic Journal of Medicine February 2023, 90 (2) 81-84; DOI: https://doi.org/10.3949/ccjm.90a.22022

      From 5% to 20% of patients may have a suboptimal response or prohibitive adverse effects over a period of a few weeks to 3 months.

Back to top

In this issue